Skip to main content

Table 3 Outcome of 95 episodes of streptococcal prosthetic joint infections; univariate analysis

From: Outcome of patients with streptococcal prosthetic joint infections with special reference to rifampicin combinations

Variables Remission (n = 67) Failure (n = 28) p
Age > 70 years 35 (36.8 %) 11 (39.3 %) .25
≥1 comorbidity 46 (68.7 %) 24 (85.7 %) .09
Total hip arthroplasty 40 (42.1 %) 10 (35.7 %) .03
Type of infection (early/delayed/late) 20 (29.8 %)/18 (26.9 %)/29 (43.3 %) 11 (39.3 %)/7 (25 %)/10 (35.7 %) .19
Fever 35 (36.8 %) 17 (60.7 %) .45
CRP in mg/L, mean value ± SD 154.6 ± 121.9 207.2 ± 148.3 .09
S. agalactiae (group B streptococci) 27 (28.4 %) 10 (35.7 %) .68
Antibiotic treatment prior to admission 18 (18.9 %) 8 (28.6 %) .86
Sinus tract 15 (15.8 %) 3 (10.7 %) .18
Concomitant bacteremia at the time of diagnosis 11 (16.4 %) 8 (28.6 %) .18
DAIR 32 (33.7 %) 23 (82.1 %) .002
Primary arthroplasty 53 (79.1 %) 20 (71.4 %) .42
Hematogenous origin 10 (14.9 %) 8 (28.6 %) .12
Rifampicin based combinations 44 (46.3 %) 8 (28.6 %) .001
Rifampicin + levofloxacin 24 (25.2 %) 4 (14.3 %) .04
  1. DAIR: surgical debridement with retention of the fixed components and antibiotic therapy
  2. Results are presented in no. of cases and percentage of the total in each column